Selinexor Misses Phase 3 Endometrial Cancer Endpoint

Company Karyopharm Therapeutics Event Type Clinical Trial Results (Phase 3, Missed Primary Endpoint) Modality Oral exportin-1 (XPO1) inhibitor Asset Selinexor Target XPO1 (exportin-1) Disease Area TP53-wild-type advanced or recurrent endometrial cancer (maintenance) Summary Phase 3 XPORT-EC-042 did not meet its primary progression-free-survival endpoint for selinexor…